Treatment of Opioid-Use Disorders. by Schuckit, Marc A
UC San Diego
UC San Diego Previously Published Works
Title
Treatment of Opioid-Use Disorders.
Permalink
https://escholarship.org/uc/item/67n6v6gj
Journal
The New England journal of medicine, 375(16)
ISSN
0028-4793
Author
Schuckit, Marc A
Publication Date
2016-10-01
DOI
10.1056/nejmc1610830
 
Peer reviewed
eScholarship.org Powered by the California Digital Library
University of California
T h e  n e w  e ngl a nd  j o u r na l  o f  m e dic i n e
n engl j med 375;16 nejm.org October 20, 20161596
Treatment of Opioid-Use Disorders
To the Editor: In his review of the management 
of opioid-use disorders, Schuckit (July 28 issue)1 
focuses on withdrawal syndromes and the cen-
tral role of opioid-agonist maintenance therapy 
in long-term rehabilitation. However, patients 
must first engage in treatment in order for the 
therapeutic approaches described to be imple-
mented. Increasingly, patients with opioid-use 
disorders come into contact with the health care 
system because of hospitalization for other rea-
sons such as infection, pregnancy, or trauma.2 
Such hospitalizations provide a brief but unique 
opportunity to offer treatment for opioid-use dis-
orders.
The use of methadone and buprenorphine for 
adjunctive treatment of opioid-use disorders dur-
ing such hospitalizations is recommended by 
international guidelines, and under the Code of 
Federal Regulations (21 CFR 1306.07), any hos-
pital-based provider is explicitly allowed to pro-
vide this treatment.3,4 However, hospital phar-
macies and medical providers vary in their 
interpretations of this regulation, and many 
health systems prohibit or limit the use of these 
agents for hospitalized patients with opioid-use 
disorders. Policies are needed to clarify and 
standardize this practice in order to engage this 
most vulnerable patient population in treatment 
for addiction.
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To the Editor: Schuckit’s review article attempts 
to provide “an overview of the current treatment 
of opioid-related conditions.” However, the arti-
cle does not meaningfully address what happens 
after an addicted patient has been helped through 
withdrawal with the use of pharmacologic agents 
and then enters a pharmacologic maintenance 
program. Although both of these approaches are 
extremely important, sadly, the inability of most 
of these patients to achieve lifetime sobriety means 
that pharmacologic successes ultimately fail.
A spiritual defect develops wherein addicted 
patients use chemicals to replace hope and faith 
that a normal life will work satisfactorily.1 The 
chemicals in turn cause major biologic, social, 
and psychological problems. The spiritual defect 
can be addressed only with a spiritual solution, 
and the only widely available and effective long-
lasting spiritual treatments of addiction are the 
12-step Alcoholics Anonymous and Narcotics 
Anonymous programs. Millions of patients in 
Alcoholics Anonymous, Narcotics Anonymous, or 
both of these programs agree with the Big Book 
of Alcoholics Anonymous, which says that “rare-
ly have we seen a person fail who had thoroughly 
followed our path.”2 Short-term pharmacologic 
success in persons with addiction must be fol-
lowed by long-term spiritual healing.
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The author replies: In this article as in many 
review articles, judgments had to be made re-
garding which of the many issues that relate to 
the topic would be included and the amount of 
space they would occupy.
Winetsky et al. note the challenges associated 
with engaging patients who have substance-use 
disorders in treatment; doing so is an essential 
first step before therapeutic interventions can be 
instituted. They also emphasize the available op-
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portunities for intervention when persons seek 
care for other medical reasons, as well as the 
need to clarify and standardize ways to imple-
ment the relevant Code of Federal Regulations 
regarding treatments in clinical settings. Too 
many health care systems inappropriately pro-
hibit these approaches. These points are worth 
emphasizing, and approaches for identification 
of substance-use disorders and interventions were 
major points in my 2009 review of the treatment 
of alcohol-use disorders.1
Benumof’s points expand on my comments 
and associated references1,2 in the second para-
graph of the section “Approaches to Rehabilita-
tion and Maintenance” of my article. He empha-
sizes the key roles played by self-help groups 
such as Alcoholics Anonymous and Narcotics 
Anonymous in recovery from substance-use dis-
orders. These 12-step programs offer round-the-
clock guidance from nonprofessionals who are 
themselves in recovery; assist with relapse pre-
vention; provide models of how abstinence can 
develop and be maintained; and introduce mem-
bers to peers who are not abusing alcohol or 
drugs. In addition to these elements of what 
might be considered to be cognitive behavioral 
approaches, most groups stress the importance 
of spiritual growth. Regardless of which of these 
many elements are most essential to specific 
members, I echo Benumof’s enthusiasm for these 
programs.
Finally, another valued colleague (Skolnick P: 
personal communication) made an informal com-
ment that I want to convey to readers. The Food 
and Drug Administration recently approved an 
intranasal formulation of naloxone for treating 
opioid overdoses.3
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Long-Term Follow-up of TBI
To the Editor: An article by Okie (July 14 issue)1 
on traumatic brain injury (TBI) focused on the 
personal paths to recovery taken by combat veter-
ans with TBI. The article, however, gave an erro-
neous impression that previous research on the 
long-term effects of TBI has been scarce. In fact, 
there is considerable published literature on this 
topic that could guide present and future re-
search and clinical management of both closed 
(including blast-related2) and penetrating TBI. 
Even if it is difficult to predict with absolute cer-
tainty a precise outcome after TBI in any indi-
vidual patient, there are key preinjury and post-
injury indicators that can greatly help clinicians 
forecast potential issues (e.g., return to work3) 
for patients with TBI, including preinjury cogni-
tive ability, genetic polymorphisms, and post-
injury evaluation of physical, epilepsy, and neuro-
behavioral status.4-6 In treating veterans with 
TBI, it is our responsibility to know this litera-
ture and do everything we can to improve care.
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